| Literature DB >> 34084122 |
Kelan Nesbitt1, Pranav Sharma1.
Abstract
INTRODUCTION: Minimally invasive partial nephrectomy is standard of care treatment for small renal masses.Entities:
Keywords: Complications; Minimally invasive surgery; Partial nephrectomy; Renal mass; Subcutaneous fat; Visceral fat
Year: 2021 PMID: 34084122 PMCID: PMC8137042 DOI: 10.1097/CU9.0000000000000001
Source DB: PubMed Journal: Curr Urol ISSN: 1661-7649
Figure 1Measurement technique of subcutaneous fat thickness on axial computed tomography scan image.
Figure 2Measurement technique of subcutaneous fat index (A-red) and visceral fat index (B-blue) on axial CT scan image.
Figure 3Measurement technique of perinephric fat thickness on axial CT scan image.
Patient sociodemographics and clinical characteristics.
| No high-grade complications (n = 93) | High-grade complications (n = 5) | Total (n = 98) |
| |
|---|---|---|---|---|
| Mean age, y | 56.6 ± 13.6 | 58.6 ± 18.7 | 56.7 ± 13.8 | 0.75 |
| Mean BMI, kg/m2 | 33.2 ± 12.5 | 28.9 ± 9.2 | 33.0 ± 12.4 | 0.50 |
| Race, n (%) | 0.79 | |||
| Non-hispanic white | 49 (52.7) | 3 (60.0) | 52 (53.1) | |
| Hispanic white | 36 (38.7) | 2 (40.0) | 38 (38.8) | |
| Black | 8 (8.6) | 0 (0.0) | 8 (8.2) | |
| Gender, n (%) | 0.028 | |||
| Male | 46 (49.5) | 5 (100.0) | 51 (52.0) | |
| Female | 47 (50.5) | 0 (0.0) | 47 (48.0) | |
| History of tobacco abuse, n (%) | 0.44 | |||
| None | 53 (57.0) | 3 (60.0) | 56 (57.1) | |
| Former | 19 (20.4) | 0 (0.0) | 19 (19.4) | |
| Current | 21 (22.6) | 2 (40.0) | 23 (23.5) | |
| Prior abdominal surgery, n (%) | 0.18 | |||
| No | 46 (49.5) | 4 (80.0) | 50 (51.0) | |
| Yes | 47 (50.5) | 1 (20.0) | 48 (49.0) | |
| ASA score, n (%) | 0.34 | |||
| 1–2 | 36 (38.7) | 3 (60.0) | 39 (39.8) | |
| 3–4 | 57 (61.3) | 2 (40.0) | 59 (60.2) | |
| CCI, n (%) | 0.99 | |||
| 0–3 | 38 (40.9) | 2 (40.0) | 40 (40.8) | |
| 4–5 | 38 (40.9) | 2 (40.0) | 40 (40.8) | |
| ≥6 | 17 (18.3) | 1 (20.0) | 18 (18.4) | |
| Diabetes, n (%) | 0.81 | |||
| No | 70 (75.3) | 4 (80.0) | 74 (75.5) | |
| Yes | 23 (24.7) | 1 (20.0) | 24 (24.5) | |
| CKD, n (%) | 0.20 | |||
| No | 77 (82.8) | 3 (60.0) | 80 (81.6) | |
| Yes | 16 (17.2) | 2 (40.0) | 18 (18.4) | |
| Mean preoperative Cr, mg/dL | 0.95 ± 0.33 | 0.93 ± 0.15 | 0.95 ± 0.33 | 0.93 |
| Mean preoperative eGFR, mL/min/1.73 m2 | 81 ± 25 | 93 ± 26 | 82 ± 24 | 0.42 |
| Mean subcutaneous fat thickness, cm | 2.64 ± 1.26 | 1.54 ± 0.52 | 2.59 ± 1.25 | 0.054 |
| Mean subcutaneous fat index, cm2 | 263 ± 149 | 143 ± 63 | 257 ± 148 | 0.079 |
| Mean perinephric fat thickness, cm | 1.98 ± 1.27 | 2.70 ± 2.11 | 2.02 ± 1.32 | 0.24 |
| Mean visceral fat index, cm2 | 176 ± 106 | 242 ± 275 | 180 ± 118 | 0.23 |
ASA = American Society of Anesthesiologists, CCI = comprehensive complication index, CDK = chronic kidney disease.
Patient disease-specific characteristics.
| No high-grade complications (n = 93) | High-grade complications (n = 5) | Total (n = 98) |
| |
|---|---|---|---|---|
| Mean nephrometry score, n | 6.6 ± 2.1 | 7.0 ± 3.3 | 6.7 ± 2.2 | 0.72 |
| Tumor location, n (%) | 0.30 | |||
| Anterior | 33 (35.5) | 2 (20.0) | 35 (35.7) | |
| Posterior | 32 (34.4) | 3 (60.0) | 35 (35.7) | |
| Lateral | 28 (30.1) | 0 (0.0) | 28 (28.6) | |
| Hilar location, n (%) | 0.30 | |||
| No | 74 (79.6) | 3 (60.0) | 77 (78.6) | |
| Yes | 19 (20.4) | 2 (40.0) | 21 (21.4) | |
| Mean tumor/kidney diameter, n (%) | 29 (16) | 31 (15) | 29 (16) | 0.77 |
| Mean operative time, minutes | 223 ± 63 | 209 ± 31 | 223 ± 62 | 0.65 |
| Mean EBL, mL | 200 ± 206 | 350 ± 367 | 207 ± 216 | 0.13 |
| Mean warm ischemia time, min | 23 ± 15 | 30 ± 4 | 23 ± 14 | 0.39 |
| Intraoperative blood transfusion, n (%) | 0.52 | |||
| No | 86 (92.5) | 5 (100.0) | 91 (92.9) | |
| Yes | 7 (7.5) | 0 (0.0) | 7 (7.1) | |
| Intraoperative complication, n (%) | <0.01 | |||
| No | 93 (100.0) | 4 (80.0) | 97 (99.0) | |
| Yes | 0 (0.0) | 1 (20.0) | 1 (1.0) | |
| Mean length of stay, d | 2.5 ± 2.0 | 3.2 ± 2.5 | 2.5 ± 2.0 | 0.44 |
| Mean postoperative Cr, mg/dL | 0.91 ± 0.30 | 1.28 ± 0.36 | 0.93 ± 0.32 | 0.011 |
| Mean postoperative eGFR, mL/min/1.73 m2 | 86 ± 26 | 65 ± 21 | 85 ± 26 | 0.095 |
| Mean postoperative change in eGFR, mL/min/1.73 m2 | 10 ± 12 | 24 ± 14 | 10 ± 12 | 0.06 |
| Histology, n (%) | 0.97 | |||
| Clear cell RCC | 78 (83.9) | 5 (100.0) | 83 (84.7) | |
| Papillary RCC | 3 (3.2) | 0 (0.0) | 3 (3.1) | |
| Chromophobe RCC | 2 (2.2) | 0 (0.0) | 2 (2.0) | |
| Oncocytic RCC | 6 (6.5) | 0 (0.0) | 6 (6.1) | |
| Angiomyolipoma | 3 (3.2) | 0 (0.0) | 3 (3.1) | |
| Oncocytoma | 1 (1.1) | 0 (0.0) | 1 (1.0) | |
| Pathological T stage, n (%) | 0.88 | |||
| T1a | 72 (77.4) | 4 (80.0) | 76 (77.6) | |
| T1b | 12 (12.9) | 1 (20.0) | 13 (13.3) | |
| T2–T3 | 5 (5.4) | 0 (0.0) | 5 (5.1) | |
| Negative for malignancy | 4 (4.3) | 0 (0.0) | 4 (4.1) | |
| Pathological Fuhrman grade, n (%) | 0.53 | |||
| I–II | 74 (79.6) | 5 (100.0) | 79 (80.6) | |
| III–IV | 15 (16.1) | 0 (0.0) | 15 (15.3) | |
| Negative for malignancy | 4 (4.3) | 0 (0.0) | 4 (4.1) | |
| Surgical margins, n (%) | 0.39 | |||
| Negative | 85 (91.4) | 4 (80.0) | 89 (90.8) | |
| Positive | 8 (8.6) | 1 (20.0) | 9 (9.2) |
Predictors of postoperative 30-day high-grade complications.
| Multivariate | ||||
|---|---|---|---|---|
|
| ||||
| 95% CI | ||||
|
| ||||
| OR | Lower | Upper |
| |
| Mean ASA score | 0.10 | 0.009 | 1.19 | 0.069 |
| Mean CCI | 0.45 | 0.13 | 1.51 | 0.19 |
| Mean BMI, kg/m2 | 0.96 | 0.85 | 1.09 | 0.55 |
| Mean subcutaneous fat index, cm2 | 0.98 | 0.95 | 1.001 | 0.061 |
| Mean visceral fat index, cm2 | 1.02 | 1.002 | 1.03 |
|
| Mean nephrometry score | 1.58 | 0.81 | 3.07 | 0.18 |
ASA = American Society of Anesthesiologists, CCI = comprehensive complication index.
Bold values are statistically significant variables (p < 0.05).